Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00723190 · ClinicalTrials.gov registry record · Phase 3
Open-Label, Chronic Exposure, Safety Study of CLONICEL (Clonidine HCl Sustained Release) in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
A Phase 3 study, sponsored by Shionogi.
- Completed
- Registry status
- Phase 3
- Development phase
- 303
- Enrollment target
NCT00723190: Completed Phase 3 study, sponsored by Shionogi.
NCT00723190 is a Phase 3 study that has completed, run by Shionogi. The registered enrollment target is 303 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00723190, a Phase 3 study, has completed, sponsored by Shionogi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 303 participants
- Enrollment target
Study Summary
The purpose of this 12-month, multi-center, open-label study is to evaluate the safety of CLONICEL (clonidine HCl sustained release) when administered chronically under regular clinical conditions either as monotherapy or in combination with stimulant therapy to children and adolescents with attention deficit hyperactivity disorder (ADHD).
Primary Outcome
Safety assessments were performed at each study visit according to the time and events schedule. All safety analyses were based on safety population
Interventions
- DRUG CLONICEL (Clonidine HCl sustained release)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 303 participants |
| Start Date | 2008-01 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
What the finished NCT00723190 record still lists
NCT00723190 is an interventional study that assigns participants to a tested intervention. The registered 303 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower).
The record links to 0 conditions, and to 1 intervention - of which CLONICEL (Clonidine HCl sustained release) is the first listed.
NCT00723190 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00723190 about?
NCT00723190 is a clinical study titled "Open-Label, Chronic Exposure, Safety Study of CLONICEL (Clonidine HCl Sustained Release) in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)". The purpose of this 12-month, multi-center, open-label study is to evaluate the safety of CLONICEL (clonidine HCl sustained release) when administered chronically under regular clinical conditions either as monotherapy or in combination with stimulant therapy to children and adolescents with attenti...
What is the current status of trial NCT00723190?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 303 participants. The study started on 2008-01. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00723190?
The interventions under investigation include: CLONICEL (Clonidine HCl sustained release) (DRUG).
Who is sponsoring clinical trial NCT00723190?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00723190's enrollment target sits among peer trials
303 1119th of 2000 higher than 882 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05508971 · 303 participants · NA
Treatment of Obstructive Sleep Apnea With Personalized Surgery in Children With Down Syndrome (TOPS-DS)
- NCT04750616 · 304 participants · Phase 2
NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
- NCT04994717 · 304 participants · Phase 3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
- NCT06036147 · 304 participants · NA
Concussion Health Improvement Program
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia